Showing results (321-330 of 367) with videos related to
Sort By:
Pageof 37
EMBO Molecular Medicine|October 16, 2016
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseasesJörg T Regula, Peter Lundh von Leithner, Richard Foxton, et al.Molecular Cancer Therapeutics|July 23, 2013
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft modelsSylvia Herter, Frank Herting, Olaf Mundigl, et al.Cell Reports|February 16, 2016
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease ProgressionGiovanni Galletti, Cristina Scielzo, Federica Barbaglio, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesMarina Bacac, Sara Colombetti, Sylvia Herter, et al.Mabs|September 19, 2019
DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicityClaudio Sustmann, Steffen Dickopf, Jörg T Regula, et al.Nature Communications|April 16, 2024
The physiological interactome of TCR-like antibody therapeutics in human tissuesEstelle Marrer-Berger, Annalisa Nicastri, Angelique Augustin, et al.Blood|August 1, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphomaJohannes Sam, Gabrielle Leclercq-Cohen, Samuel Gebhardt, et al.Journal of Pharmacological and Toxicological Methods|June 12, 2026
The INSPIRE doctoral network in safety pharmacology - Looking back and aheadPieter-Jan Guns, Brigitta Rita Szabó, Martina Cherubin, et al.Journal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.Journal for Immunotherapy of Cancer|July 4, 2020
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancerMarta Trüb, Franziska Uhlenbrock, Christina Claus, et al.Pageof 37